-
公开(公告)号：US08022071B2
公开(公告)日：2011-09-20
申请号：US11959341
申请日：2007-12-18
Applicant: Anjali Pandey , Robert M. Scarborough , Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shinichi Ide , Eiji Tsukuda , Junko Sasaki , Shoji Oda
Inventor： Anjali Pandey , Robert M. Scarborough , Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shinichi Ide , Eiji Tsukuda , Junko Sasaki , Shoji Oda
IPC: A61K31/5377 , A61K31/517
CPC classification number: C07D401/12 , C07D239/94 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12
Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
Abstract translation: 本发明涉及对抑制这种激酶活性的激酶磷酸化具有抑制活性的含氮杂环化合物及其药学上可接受的盐。 本发明还涉及通过抑制激酶的磷酸化来抑制哺乳动物的激酶和治疗疾病状态的方法。 在一个特定方面，本发明提供了抑制PDGF受体的磷酸化以阻止异常细胞生长和细胞游动的含氮杂环化合物及其药学上可接受的盐，以及预防或治疗细胞增殖性疾病如动脉硬化，血管 重建，癌症和肾小球硬化症。
-
公开(公告)号：US20100113468A1
公开(公告)日：2010-05-06
申请号：US12471280
申请日：2009-05-22
Applicant: Anjali Pandey , Robert M. Scarborough , Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shinichi Ide , Eiji Tsukuda , Junko Sasaki , Shoji Oda
Inventor： Anjali Pandey , Robert M. Scarborough , Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shinichi Ide , Eiji Tsukuda , Junko Sasaki , Shoji Oda
IPC: A61K31/497
CPC classification number: C07D239/94 , A61K31/517 , C07D401/12 , C07D403/12
Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
Abstract translation: 本发明涉及对抑制这种激酶活性的激酶磷酸化具有抑制活性的含氮杂环化合物及其药学上可接受的盐。 本发明还涉及通过抑制激酶的磷酸化来抑制哺乳动物的激酶和治疗疾病状态的方法。 在一个特定方面，本发明提供了抑制PDGF受体的磷酸化以阻止异常细胞生长和细胞游动的含氮杂环化合物及其药学上可接受的盐，以及预防或治疗细胞增殖性疾病如动脉硬化，血管 重建，癌症和肾小球硬化症。
-
公开(公告)号：US20100016250A1
公开(公告)日：2010-01-21
申请号：US12297211
申请日：2007-04-13
Applicant: Hiroyuki Nagata , Michio Ichimura , Rieko Nakatsu , Shun-Ichi Ikeda , Ayako Kawabata , Toshio Ota , Masayuki Abe , Michio Takashima , Makoto Suzuki
Inventor： Hiroyuki Nagata , Michio Ichimura , Rieko Nakatsu , Shun-Ichi Ikeda , Ayako Kawabata , Toshio Ota , Masayuki Abe , Michio Takashima , Makoto Suzuki
IPC: A61K31/7064 , C12P19/30 , C12P19/32 , C12N1/20 , A61K31/7076 , C07H19/20 , C07H19/10 , A61P31/00 , A61K31/7072 , C07H19/24 , A61K31/708 , A61P37/04 , A61P25/00
CPC classification number: C07H19/20 , C07H19/10 , C12N15/117 , C12N2310/17 , C12N2310/351 , C12P19/30
Abstract: The present invention provides TLR9 agonists comprising, as an active ingredient, a compound represented by formula (I): (wherein a represents 0 or 1; n represents an integer of 0 to 2; m represents an integer of 0 to 5; X1 and X2 each independently represent a hydrogen atom or hydroxy; Y represents an oxygen atom or a sulfur atom; -Q1-represents —O— or the like; -Q2- represents —O— or the like; -Z- represents —O— or the like; R1, R3 and R4 each independently represent hydroxy or the like; R2 and R5 each independently represent a hydrogen atom, hydroxy or the like; and A represents 6-aminopurin-9-yl or the like) or a pharmaceutically acceptable salt thereof, and the like.
Abstract translation: 本发明提供TLR9激动剂，其包含作为活性成分的由式（I）表示的化合物：（其中a表示0或1; n表示0〜2的整数; m表示0〜5的整数; X1和 X2各自独立地表示氢原子或羟基; Y表示氧原子或硫原子; -Q1表示-O-等; -Q2-表示-O-等; -Z-表示-O-或 类似物; R 1，R 3和R 4各自独立地表示羟基等; R 2和R 5各自独立地表示氢原子，羟基等; A表示6-氨基嘌呤-9-基等）或药学上可接受的盐 等等。
-
公开(公告)号：US20060063770A1
公开(公告)日：2006-03-23
申请号：US11200456
申请日：2005-08-08
Applicant: Anjali Pandey , Robert Scarborough , Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shinichi Ide , Eiji Tsukuda , Junko Sasaki , Shoji Oda
Inventor： Anjali Pandey , Robert Scarborough , Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shinichi Ide , Eiji Tsukuda , Junko Sasaki , Shoji Oda
IPC: A61K31/517
CPC classification number: C07D401/12 , C07D239/94 , C07D403/12
Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
Abstract translation: 本发明涉及对抑制这种激酶活性的激酶磷酸化具有抑制活性的含氮杂环化合物及其药学上可接受的盐。 本发明还涉及通过抑制激酶的磷酸化来抑制哺乳动物的激酶和治疗疾病状态的方法。 在一个特定方面，本发明提供了抑制PDGF受体的磷酸化以阻止异常细胞生长和细胞游动的含氮杂环化合物及其药学上可接受的盐，以及预防或治疗细胞增殖性疾病如动脉硬化，血管 重建，癌症和肾小球硬化症。
-
公开(公告)号：US20060058366A1
公开(公告)日：2006-03-16
申请号：US10536881
申请日：2003-12-03
Applicant: Fumihiko Kanai , Toshiaki Kumazawa , Jun-ichi Saito , Junichi Shimada , Ryo Hirose , Michio Ichimura
Inventor： Fumihiko Kanai , Toshiaki Kumazawa , Jun-ichi Saito , Junichi Shimada , Ryo Hirose , Michio Ichimura
IPC: A61K31/416 , C07D231/56
CPC classification number: A61K31/4439 , A61K31/416 , A61K31/444 , A61K31/497 , C07D231/56 , C07D401/06
Abstract: The present invention provides a JNK inhibitor comprising, as an active ingredient, an indazole derivative represented by Formula (I) [wherein R1 represents substituted or unsubstituted aryl or the like and R2 represents a hydrogen atom, NR3R4 (wherein R3 and R4 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkanoyl or the like), carboxy, lower alkenyl or the like] or a pharmaceutically acceptable salt thereof.
Abstract translation: 本发明提供一种JNK抑制剂，其包含作为活性成分的式（I）表示的吲唑衍生物，
-
Patent Agency Ranking
公开(公告)号：US20050288297A1
公开(公告)日：2005-12-29
申请号：US11210028
申请日：2005-08-22
Applicant: Anjali Pandey , Robert Scarborough , Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shinichi Ide , Eiji Tsukuda , Junko Sasaki , Shoji Oda
Inventor： Anjali Pandey , Robert Scarborough , Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shinichi Ide , Eiji Tsukuda , Junko Sasaki , Shoji Oda
IPC: A61K31/517 , A61K31/5377 , A61K31/541 , A61P9/08 , A61P9/10 , A61P13/12 , A61P35/00 , A61P43/00 , C07D239/94 , C07D401/12 , C07D403/12
CPC classification number: C07D239/94 , A61K31/517 , C07D401/12 , C07D403/12
Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
Abstract translation: 本发明涉及对抑制这种激酶活性的激酶磷酸化具有抑制活性的含氮杂环化合物及其药学上可接受的盐。 本发明还涉及通过抑制激酶的磷酸化来抑制哺乳动物的激酶和治疗疾病状态的方法。 在一个特定方面，本发明提供了抑制PDGF受体的磷酸化以阻止异常细胞生长和细胞游动的含氮杂环化合物及其药学上可接受的盐，以及预防或治疗细胞增殖性疾病如动脉硬化，血管 重建，癌症和肾小球硬化症。
-
公开(公告)号：US20050101609A1
公开(公告)日：2005-05-12
申请号：US10344736
申请日：2001-08-17
Applicant: Anjali Pandey , Robert Scarborough , Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shinichi Ide , Eiji Tsukuda , Junko Sasaki , Shoji Oda
Inventor： Anjali Pandey , Robert Scarborough , Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shinichi Ide , Eiji Tsukuda , Junko Sasaki , Shoji Oda
IPC: A61K31/517 , A61K31/5377 , A61K31/541 , A61P9/08 , A61P9/10 , A61P13/12 , A61P35/00 , A61P43/00 , C07D239/94 , C07D401/12 , C07D403/12 , C07D43/04 , C07D43/14
CPC classification number: C07D239/94 , A61K31/517 , C07D401/12 , C07D403/12
Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method ol inhibiling kinascs and tre ating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention prtvides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
Abstract translation: 本发明涉及对抑制这种激酶活性的激酶磷酸化具有抑制活性的含氮杂环化合物及其药学上可接受的盐。 本发明还涉及一种通过抑制激酶的磷酸化来抑制哺乳动物抑制哺乳动物的疾病状态的方法。 在一个特定方面，本发明提供了抑制PDGF受体的磷酸化阻碍异常细胞生长和细胞游动的含氮杂环化合物及其药学上可接受的盐，以及用于预防或治疗细胞增殖性疾病如动脉硬化的方法 ，血管重构，癌症和肾小球硬化症。
-
公开(公告)号：US06750218B2
公开(公告)日：2004-06-15
申请号：US10227302
申请日：2002-08-26
Applicant: Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shigeki Fujiwara , Shinichi Ide , Eiji Tsukuda , Junko Irie , Shoji Oda
Inventor： Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shigeki Fujiwara , Shinichi Ide , Eiji Tsukuda , Junko Irie , Shoji Oda
IPC: C07D48704
CPC classification number: C07D401/12 , A61K31/496 , A61K31/502 , A61K31/517 , C07D215/46 , C07D217/22 , C07D237/34 , C07D239/94 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D487/04
Abstract: 1,3 Diazines according to formula: and pharmaceutically acceptable salts thereof inhibit phosphorylation of platelet-derived growth factor receptor and thereby hinder abnormal cell growth and cell wandering.
Abstract translation: 1,3根据式的二嗪类及其药学上可接受的盐抑制血小板衍生生长因子受体的磷酸化，从而阻碍异常细胞生长和细胞游动。
-
9.发明授权公开(公告)号：US06207667B1
公开(公告)日：2001-03-27
申请号：US09481544
申请日：2000-01-12
Applicant: Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shigeki Fujiwara , Shinichi Ide , Eiji Tsukuda , Junko Irie , Shoji Oda
Inventor： Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shigeki Fujiwara , Shinichi Ide , Eiji Tsukuda , Junko Irie , Shoji Oda
IPC: A61K31535
CPC classification number: C07D401/12 , A61K31/496 , A61K31/502 , A61K31/517 , C07D215/46 , C07D217/22 , C07D237/34 , C07D239/94 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D487/04
Abstract: 1,3 Diazines according to formula (I): and pharmaceutically acceptable salts thereof inhibit phosphorylation of platelet-derived growth factor receptor and thereby hinder abnormal cell growth and cell wandering. The compounds may be used to treat or prevent cell-proliferative disorders such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
Abstract translation: 1,3根据式（I）的二嗪类及其药学上可接受的盐抑制血小板衍生生长因子受体的磷酸化，从而阻碍异常细胞生长和细胞游动。 该化合物可用于治疗或预防细胞增殖性疾病如动脉硬化，血管重构，癌症和肾小球硬化。
-
10.发明授权1,3 diazines with platelet-derived growth factor receptor inhibitory activity 失效1,3二嗪与血小板衍生生长因子受体的抑制活性公开(公告)号：US06169088A
公开(公告)日：2001-01-02
申请号：US09088199
申请日：1998-06-01
Applicant: Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shigeki Fujiwara , Shinichi Ide , Eiji Tsukuda , Junko Irie , Shoji Oda
Inventor： Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shigeki Fujiwara , Shinichi Ide , Eiji Tsukuda , Junko Irie , Shoji Oda
IPC: A61K31495
CPC classification number: C07D401/12 , A61K31/496 , A61K31/502 , A61K31/517 , C07D215/46 , C07D217/22 , C07D237/34 , C07D239/94 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D487/04
Abstract: 1,3 Diazines and pharmaceutically acceptable salts thereof inhibit phosphorylation of platelet-derived growth factor receptor and thereby hinder abnormal cell growth and cell wandering. The compounds may be used to treat or prevent cell-proliferative disorders such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
Abstract translation: 1,3二嗪及其药学上可接受的盐抑制血小板衍生生长因子受体的磷酸化，从而阻碍异常细胞生长和细胞游动。 该化合物可用于治疗或预防细胞增殖性疾病如动脉硬化，血管重构，癌症和肾小球硬化。
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.044 seconds)
